Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The company reported a strong performance in 2024, with total revenue reaching 104.906 billion yuan, a year-on-year increase of 16.66%, and a net profit attributable to shareholders of 9.245 billion yuan, up 244.68% year-on-year [6][7] - The pig farming segment has turned profitable, becoming the core driver of profit growth, with a total pig output of 30.1827 million heads, an increase of 14.93% year-on-year, and an average selling price of 16.71 yuan/kg, up 12.83% year-on-year [6][7] - The poultry segment demonstrated resilience, with chicken output of 1.208 billion heads, a year-on-year increase of 2.09%, despite a 4.60% decline in average selling price to 13.06 yuan/kg [6][7] Summary by Relevant Sections Financial Performance - The company forecasts revenue for 2024, 2025, and 2026 to be 104.402 billion yuan, 101.369 billion yuan, and 108.541 billion yuan respectively, with net profits of 9.257 billion yuan, 6.704 billion yuan, and 9.952 billion yuan respectively [4][7] - Earnings per share (EPS) are projected to be 1.39 yuan, 1.01 yuan, and 1.50 yuan for the years 2024, 2025, and 2026 respectively [4][7] Cost Management - The comprehensive cost of pig farming is expected to decrease further, with a target of 13 yuan/kg for 2025, providing a safety net for the company's performance amid price fluctuations [6][7] - In the poultry segment, the company managed to reduce costs more significantly than the decline in chicken prices, leading to profit growth despite market pressures [6][7] Market Outlook - The recovery of pig farming capacity is expected to be slow, limiting supply growth in 2025, which will constrain price adjustments [6][7] - The company aims to maintain its leading position in the industry through efficient production and cost management strategies [6][7]

Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The company reported a strong performance in 2024, with total revenue reaching 104.906 billion yuan, a year-on-year increase of 16.66%, and a net profit attributable to shareholders of 9.245 billion yuan, up 244.68% year-on-year [6][7] - The pig farming segment has turned profitable, becoming the core driver of profit growth, with a total pig output of 30.1827 million heads, a year-on-year increase of 14.93% [6][7] - The company aims to maintain a competitive edge in pig farming costs, targeting an average comprehensive cost of 13 yuan per kilogram for 2025 [6][7] Summary by Sections Financial Performance - The company’s main revenue for 2022 was 83.708 billion yuan, projected to increase to 104.402 billion yuan in 2024 and 101.369 billion yuan in 2025 [4][9] - The net profit attributable to shareholders was -6.390 billion yuan in 2023, expected to recover to 9.257 billion yuan in 2024 and 6.704 billion yuan in 2025 [4][9] - Earnings per share (EPS) is projected to be 1.39 yuan in 2024, decreasing to 1.01 yuan in 2025, and then increasing to 1.50 yuan in 2026 [4][9] Business Segments - In the pig farming sector, the average selling price of pigs was 16.71 yuan per kilogram in 2024, a year-on-year increase of 12.83%, with comprehensive costs significantly reduced to 14.4 yuan per kilogram [6][7] - The poultry segment saw a slight increase in chicken output to 1.208 billion heads, despite a decrease in average selling price to 13.06 yuan per kilogram [6][7] Future Outlook - The company expects to maintain its profitability in the pig farming sector due to a slow recovery in production capacity, which will limit the supply growth in 2025 [6][7] - The company has set a target for pig output in 2025 to be between 33 million and 35 million heads, focusing on quality and steady growth [6][7]

Investment Rating - The investment rating for the company is "Buy" [4][6][8] Core Views - The company is driven by AI and cloud platform initiatives, with a focus on accelerating the deployment of smart home hardware [2][5] - Revenue is projected to grow steadily, with expected figures of 54.42 billion yuan in 2024, 62.18 billion yuan in 2025, and 70.12 billion yuan in 2026, reflecting a compound annual growth rate [2][6] - The company is currently in a growth phase, investing heavily in marketing and channel expansion, which is anticipated to enhance profitability in the future [6][7] Financial Projections - Main revenue figures (in billion yuan): - 2022A: 43.06 - 2023A: 48.40 - 2024E: 54.42 - 2025E: 62.18 - 2026E: 70.12 [2][7] - Net profit attributable to shareholders (in billion yuan): - 2022A: 3.33 - 2023A: 5.63 - 2024E: 5.04 - 2025E: 6.07 - 2026E: 7.60 [2][7] - Earnings per share (EPS) projections: - 2022A: 0.42 - 2023A: 0.71 - 2024E: 0.64 - 2025E: 0.77 - 2026E: 0.97 [2][7] Market Position and Strategy - The company is focusing on expanding its smart home ecosystem, with key products including smart cameras, smart locks, and service robots [5][6] - The smart camera segment is expected to recover due to policy support and promotional events, while the smart lock segment is experiencing significant growth in both domestic and international markets [4][5] - The company is leveraging user behavior data to enhance its service offerings, creating a more integrated experience for consumers [5][6]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected investment return exceeding 15% compared to the CSI 300 index [4][8]. Core Insights - The company is experiencing robust revenue growth driven by AI and cloud platform services, with projected revenues of CNY 54.42 billion in 2024, representing a year-on-year increase of 12.41% [4][6]. - Despite revenue growth, net profit is expected to decline by 10.52% year-on-year to CNY 5.04 billion in 2024, primarily due to increased expenses [4][6]. - The company is actively expanding its market presence and product categories, which has led to higher marketing expenditures, but this is anticipated to enhance profitability in the long run [6]. Financial Projections - Revenue projections for the company are as follows: CNY 54.42 billion in 2024, CNY 62.18 billion in 2025, and CNY 70.12 billion in 2026 [4][7]. - Net profit estimates are CNY 5.04 billion for 2024, CNY 6.07 billion for 2025, and CNY 7.60 billion for 2026 [4][7]. - Earnings per share (EPS) are projected to be CNY 0.64 in 2024, CNY 0.77 in 2025, and CNY 0.97 in 2026 [4][7]. Business Strategy and Market Position - The company is focusing on enhancing its full-home smart ecosystem, with significant growth in smart camera and smart door lock segments [4][5]. - The smart camera segment, despite facing challenges, is expected to recover due to policy support and promotional events [4][5]. - The company is also expanding its offerings in the service robot market, targeting both consumer and business applications, which shows promising growth potential [4][5].

Investment Rating - The investment rating for the company is "Buy" with the rating maintained [1][10] Core Views - The company is expected to achieve a net profit attributable to the parent company of approximately 300 million to 310 million yuan in 2024, representing a year-on-year increase of 32.73% to 37.15% [6] - The company has a strong product pipeline and is expanding its product matrix, which is expected to drive significant growth [6][7] - The company has established a comprehensive online and offline sales network, achieving notable market recognition in the maternal and infant care product segment [6][7] Financial Projections - Revenue projections for 2024, 2025, and 2026 are 1.349 billion, 1.716 billion, and 2.147 billion yuan respectively, with year-on-year growth rates of 30.64%, 27.18%, and 25.11% [7] - Net profit projections for the same years are 304.45 million, 382.81 million, and 470.12 million yuan, with corresponding growth rates of 34.70%, 25.74%, and 22.81% [7] - Earnings per share (EPS) are projected to be 0.75, 0.95, and 1.16 yuan for 2024, 2025, and 2026 respectively [7] Market Position and Strategy - The company is positioned as a leading player in the domestic infant care sector, focusing on meeting diverse consumer needs through continuous innovation and differentiated product offerings [6][7] - The company has successfully launched new products in the mosquito repellent and infant care categories, enhancing its market competitiveness [6][7] - The company is actively expanding its offline distribution channels, collaborating with major retailers to enhance market presence [6][7]

Market Overview - The A-share market shows a general upward trend with the major indices experiencing gains, particularly the Sci-Tech 50 index which rose by 2.17% [6][9] - The total market capitalization of the Shanghai Composite Index is 644,895 million, with a PE ratio of 12.01 and a PB ratio of 1.27 [3] Industry Dynamics - The cosmetics contract manufacturer, Cosmax, reported a 4.9% increase in sales in China for 2024, reaching 574.3 billion KRW (approximately 3.035 billion RMB) [28] - Hisense Visual Technology has partnered with XREAL to launch their first AR/AI glasses in the second half of this year, indicating a push towards integrating AR and AI technologies in various sectors [31] - The pig farming industry is facing challenges, with a decline in sales volume and prices reported for January, attributed to seasonal factors and reduced operational days during the Spring Festival [34][35] - Several photovoltaic companies participated in a fair competition seminar, highlighting the industry's focus on maintaining a competitive market environment [36] Company Tracking - Captech (003008.SZ) reported a 45.52% increase in net profit for 2024, driven by growth in their testing services and a favorable change in corporate tax rates [38][39] - Warner Pharmaceuticals (688799.SH) announced a decline in net profit by 25.19% for 2024, primarily due to increased R&D expenses and a decrease in sales prices of their main products [40][41]

Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The report highlights that Marubi Biotech has received approval for the first domestic Class III medical device registration for hydroxyapatite microspheres, indicating a significant advancement in its "dual beauty integration" strategy [6][8] - The company is expected to maintain steady growth, with projected revenues of 28.92 billion, 35.90 billion, and 42.58 billion yuan for 2024, 2025, and 2026 respectively, reflecting year-on-year growth rates of 29.94%, 24.15%, and 18.60% [9] - The report emphasizes the strong market demand for hydroxyapatite products, with a compound annual growth rate of 16% in the U.S. from 2017 to 2022, outpacing other aesthetic treatments [8] Summary by Sections Investment Rating - The company maintains an "Overweight" rating, indicating a relative performance expectation of 5%-15% above the market index [12] Financial Performance - The forecasted main revenue figures are as follows: 17.32 billion yuan in 2022, 22.26 billion yuan in 2023, 28.92 billion yuan in 2024, 35.90 billion yuan in 2025, and 42.58 billion yuan in 2026 [7] - The projected net profit attributable to shareholders is expected to grow from 1.74 billion yuan in 2022 to 5.33 billion yuan in 2026, with corresponding EPS increasing from 0.43 yuan to 1.33 yuan [7][9] Market Position and Strategy - Marubi Biotech is actively expanding into the color cosmetics sector with its new brand "Lianhuo," focusing on the base makeup segment, which is expected to serve as a second growth engine [9] - The company has made strategic investments in various beauty and health-related firms, enhancing its market presence and growth potential [8][9]

评级 增持 评级变动 维持 | 交易数据 | | | --- | --- | | 当前价格（元） | 30.60 | | 52 周价格区间（元） | 20.56-36.17 | | 总市值（百万） | 12270.60 | | 流通市值（百万） | 12270.60 | | 总股本（万股） | 40100.00 | 涨跌幅比较 % 1M 3M 12M 丸美生物 -9.14 1.86 4.69 化妆品 1.31 -5.01 -0.39 -31% -11% 9% 29% 2024-02 2024-05 2024-08 2024-11 2025-02 丸美生物 化妆品 张曦月 分析师 执业证书编号:S0530522020001 zhangxiyue@hnchasing.com 2025 年 02 月 20 日 相关报告 | 1 美容护理行业 2025 年度策略：稳中求变，守 | | --- | | 正出奇 2025-01-23 | | 2 医美专题系列一：重组胶原蛋白赛道高景气延 | 续，先行者前景可期 2025-01-02 证券研究报告 公司点评 丸美生物(603983.SH) 美容护理｜ 化妆品 投资企业获批国 ...

Market Overview - The A-share market is experiencing fluctuations, with the major indices showing mixed performance. The Shanghai Composite Index closed at 3346.04, down 0.80%, while the ChiNext Index fell by 1.13% to 2240.59. The STAR Market 50 Index, however, saw a slight increase of 0.26% to 1102.90 [2][6][8] - The total market capitalization of the Shanghai Composite Index is 638,939 million, with a price-to-earnings (PE) ratio of 11.90 and a price-to-book (PB) ratio of 1.26. The ChiNext Index has a PE ratio of 34.05 and a PB ratio of 4.33, indicating a higher valuation compared to the broader market [3] Industry Dynamics - The global ICT market is projected to reach a size of approximately 751.76 billion USD by 2028, with a compound annual growth rate (CAGR) of 6.5% over the next five years. This growth is driven by policy stimulation and emerging technology products [28] - The price of photovoltaic glass is expected to rise in March, with recent reports indicating an increase in pricing due to supply-demand mismatches and production constraints [30] - World Advanced predicts a 8% to 10% increase in wafer shipments for Q1 2025, driven by demand recovery and supply chain adjustments [27] Company Updates - TeBao Bio (688278.SH) reported a net profit of 828 million yuan for 2024, marking a 49% year-on-year increase, attributed to strong sales of its hepatitis B treatment [32] - YanJinPuZi (002847.SZ) plans to establish a wholly-owned subsidiary in Thailand with an investment of approximately 219.95 million yuan, aimed at expanding its overseas business [34] - HuaTe Gas (688268.SH) achieved a net profit of 181.23 million yuan in 2024, a 5.91% increase despite a decline in total revenue [36] - KangTuo Medical (688314.SH) reported a net profit of 88.57 million yuan for 2024, reflecting a 17.30% growth, driven by increased market penetration of its neurosurgical products [38] - JinBo Bio (832982.BJ) announced a significant net profit increase of 144.65% for 2024, reaching 733 million yuan, supported by strong sales growth in medical devices and skincare products [39] - BaiRen Medical (688198.SH) achieved a net profit of approximately 145 million yuan in 2024, a 26.26% increase, with all three business segments showing growth [41] - SaiEnSi (688480.SH) reported a net profit increase of 56.60% for 2024, driven by significant growth in sales and investment returns from joint ventures [43]

证券研究报告 金工点评报告 刘飞彤 分析师 执业证书编号:S0530522070001 liufeitong@hnchasing.com 相关报告 金工三维情绪模型更新（20250220）： 2025 年 02 月 21 日 上证 50-沪深 300-中证 500 走势图 -13% -3% 7% 17% 27% 上证50 沪深300 中证500 指数估值 | 指数名称 | PE中位数 | PB 中位数 | | --- | --- | --- | | 上证 50 | 1.99 | 14.85 | | 沪深 300 | 2.03 | 19.17 | | 中证 500 | 2.14 | 22.37 | 沪深 300 股指期货升贴水率= 沪深 300 股指期货主力价格− 沪深 300 指数价格 沪深 300 指数价格 $${\hat{\mathbb{R}}}\times{\hat{\mathbb{R}}}\times{\hat{\mathbb{R}}}={\frac{{\hat{\mathbb{R}}}\oplus{\hat{\mathbb{R}}}\oplus{\hat{\mathbb{R}}}\oplus{\ha ...